Principal Scientist, In Vivo Pharmacology, Neurology

Fully Remote Remote Worker - U.S. Research and Translational Science

Job Type

Full-time

Description

Gondola Bio is a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics for genetic diseases. Gondola Bio is an independent sister company to Bridge Bio, originally carved out in 2024 after securing $300M in private financing from external investors. Gondola Bio aims to leverage cutting-edge biological research to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases.

You are an experienced in vivo pharmacology scientist with expertise in Neurology. You have demonstrated success in developing and/or applying in vivo disease models to drug discovery campaigns. You have extensive hands‑on experience with rodent Neurology model characterization, test article dosing, tissue processing, and common wet lab techniques (e.g. qPCR, Western blot, ELISA). You are execution‑oriented, capable of driving work through CROs and external partners, and thrive in a fast‑paced biotech environment.

• Design and execute on in vivo pharmacology studies across multiple Neurology programs in our research portfolio in rodents and non-human primates, with goals of IND submission.
• Partner with toxicology and translational teams to ensure our in vivo pharmacology data package is rigorous, reproducible, and translatable — directly informing dose selection and go/no-go decisions.
• Develop and implement pharmacodynamic and efficacy assessments, troubleshoot assays, and QC data from CROs and external partners.
• Manage CRO relationships and monitor study progress for ongoing studies, identifying emerging risks, while presenting progress updates in team meetings.
• Analyze data from in vivo pharmacology endpoints including PK/bioanalysis and pharmacodynamic and/or efficacy endpoints.

• Bachelor’s degree and 6+ years of biopharmaceutical industry experience within in vivo pharmacology.
• Experience with small molecules and antisense oligonucleotides (ASOs) is preferred.
• Experience in rare disease or developmental and epileptic encephalopathy (DEE) models is strongly preferred.
• Strong intellectual curiosity as demonstrated by routine engagement with scientific community and familiarity with literature.
• Direct experience and willingness to continue to design pharmacology studies with direct involvement and leading coordination of external efforts.
• Exposure to IND-enabling studies and experience writing regulatory or technical reports.
• Ability to operate independently and cross‑functionally in a lean, fast‑moving biotech environment.

• Patient Champions who put patients first, uphold strict ethical standards, and anchor decisions in clinical and scientific integrity.
• Entrepreneurial Operators who take ownership and drive toward practical solutions, while exercising sound judgment, respecting established processes, and aligning with teammates and leadership.
• Truth Seekers who are rigorous, detail‑oriented, and intellectually honest—comfortable challenging assumptions, engaging with data, and updating their views based on evidence.
• Collaborative Thinkers who work effectively in data‑driven, interdisciplinary environments; listen actively; and welcome questions, debate, and constructive challenge as essential to better decision‑making.
• Individuals Who Inspire Excellence in themselves and those around them.
• High‑quality Executors who deliver against goals and milestones with precision, accountability, and appropriate urgency—without compromising scientific rigor or team alignment.